Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients

被引：0

作者：

Schweiger, Vittorio ^{[1
]}

Bellamoli, Paola ^{[1
]}

Taus, Francesco ^{[2
]}

Gottin, Leonardo ^{[1
]}

Martini, Alvise ^{[1
]}

Nizzero, Marta ^{[1
]}

Bonora, Eleonora ^{[1
]}

Del Balzo, Giovanna ^{[3
]}

Donadello, Katia ^{[1
]}

Secchettin, Erica ^{[1
]}

Finco, Gabriele ^{[4
]}

De Santis, Daniele ^{[5
]}

Polati, Enrico ^{[1
]}

机构：

[1] Univ Verona, Anesthesiol Intens Care & Pain Therapy Ctr, Dept Surg, I-37124 Verona, Italy

[2] Univ Verona, Dept Diagnost & Publ Hlth, Sect Stat, I-37124 Verona, Italy

[3] Univ Verona, Dept Diagnost & Publ Hlth, Sect Forens Med, I-37129 Verona, Italy

[4] Univ Cagliari, Dept Med Sci & Publ Hlth, I-09124 Cagliari, Italy

[5] Univ Verona, Head & Neck Dept, I-37129 Verona, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 04期

关键词：

migraine; prophylaxis; monoclonal antibodies; calcitonin gene-related peptide (CGRP); DISABILITY; MIDAS; SAFETY; HIT-6;

D O I：

10.3390/jcm13041130

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Migraine is a neurological disorder characterized by attacks of head pain with prevalent unilateral localization, moderate to high intensity and specifically associated accompanying symptoms. Methods: In this retrospective observational study, we analyzed data regarding 209 patients who had previously been diagnosed with migraine and who were prescribed, between 2019 and 2022, subcutaneous injections of anti-CGRP monoclonal antibodies (mAbs) fremanezumab or galcanezumab or anti-CGRP receptors mAb erenumab regardless of the concomitant assumption of any other acute-phase or prophylactic migraine medication. Results: Regarding efficacy, in the 205 analyzed patients, the change from baseline in terms of MIDAS, HIT-6, MMDs and MAD scores was statistically significant for erenumab and galcanezumab, while for fremanezumab a statistical significance was not achieved likely due to the small sample size. In the treated population, 36 patients (17.5%) reported AEs (pain during injection, transient injection site erythema, nausea, constipation and fatigue). Only 5 patients (2.4%) discontinued the treatment for AEs while 15 patients (7.3%) left for lack of efficacy. Conclusions: this retrospective study comes out in favor of both significant efficacy and safety of anti-CGRP and anti-CGRP receptors mAbs in migraine patients. Further methodologically stronger studies are necessary to validate our observation.

引用

页数：10